Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06309459

Enrollment

Registered

2024-03-13

Start date

2018-08-01

Completion date

2023-05-01

Last updated

2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carbonic Anhydrase IX, Triple Negative Breast Cancer

Keywords

Triple negative breast carcinoma, Carbonic anhydrase IX, Treatment effect, Ki67 proliferation index

Brief summary

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Detailed description

Tru-cut biopsy materials, sent to our hospital pathology laboratory between August 2018 and May 2023, will be examined. Invasive carcinoma cases will be evaluated according to estrogen, progesterone, and HER 2 receptor levels. Triple-negative tumor cases were isolated and those cases who underwent breast resection in our hospital after receiving neoadjuvant chemotherapy (Adriamycin, cyclophosphamide, and then paclitaxel for 4 cycles) were included in the study.

Interventions

DIAGNOSTIC_TESTCarbonic anhydrase staining levels

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Older than 18 years * Triple-negative mastectomy cases * Patients whose data can be available * Patients who were operated in our hospital

Exclusion criteria

* Younger than 18 years * Not triple negative mastectomy cases * Patients with missing data * Patients who were operated in another hospital

Design outcomes

Primary

Measure	Time frame	Description
Poor prognostic factors in patients with TNBC	2018-2023	Higher staining CA IX levels (≥ 10%) in TNBC patients' pathological specimens is a poor prognostic factor
The treatment success with inhibiting the CA IX enzyme levels' effectiveness	2018-2023	Treatment success in TNBC patients by evaluating changes in CA IX staining levels

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026